Study summary

The objective of this study is to evaluate the efficacy, pharmacokinetics, pharmacodynamics and safety of ASP1707 in combination with MTX in postmenopausal female patients with RA.

Additional Study Details

Phase
2
Product
N/A
Product
ASP1707
Placebo
Methotrexate
Type
Interventional
Masking
Double (Participant, Investigator)
Enrollment number
72
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Plain Language Summary
Available Language(s): English

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients with Rheumatoid Arthritis taking Methotrexate? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site JP00014
    Kumamoto, Kumamoto, Japan
    Completed
    Site JP00021
    Kanagawa, Kanagawa, Japan
    Completed
    Site JP00027
    Tokyo, Tokyo, Japan
    Completed
    Site JP00002
    Hokkaido, Hokkaido, Japan
    Completed
    Site JP00015
    Kumamoto, Kumamoto, Japan
    Completed
    Site JP00025
    Fukui, Fukui, Japan
    Completed
    Site JP00004
    Iwate, Iwate, Japan
    Completed
    Site JP00024
    Gunma, Gunma, Japan
    Completed
    Site JP00022
    Aichi, Aichi, Japan
    Completed
    Site JP00001
    Hokkaido, Hokkaido, Japan
    Completed
    Site JP00020
    Oita, Oita, Japan
    Completed
    Site JP00010
    Hiroshima, Hiroshima, Japan
    Completed
    Site JP00008
    Shizuoka, Shizuoka, Japan
    Completed
    Site JP00017
    Chiba, Chiba, Japan
    Completed
    Site JP00003
    Hokkaido, Hokkaido, Japan
    Completed
    Site JP00009
    Shizuoka, Shizuoka, Japan
    Completed
    Site JP00007
    Kanagawa, Kanagawa, Japan
    Completed
    Site JP00006
    Gunma, Gunma, Japan
    Completed
    Site JP00016
    Kagoshima, Kagoshima, Japan
    Completed
    Site JP00018
    Fukuoka, Fukuoka, Japan
    Completed
    Site JP00013
    Nagasaki, Nagasaki, Japan
    Completed
    Site JP00012
    Fukuoka, Fukuoka, Japan
    Completed
    Site JP00023
    Aichi, Aichi, Japan
    Completed
    Site JP00011
    Hiroshima, Hiroshima, Japan
    Completed
    Site JP00019
    Fukuoka, Fukuoka, Japan
    Completed
    Site JP00026
    Ehime, Ehime, Japan
    Completed
    Site JP00005
    Iwate, Iwate, Japan

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?